Cassidy takes aim at FDA mifepristone regulation, manufacturers
Sen. Bill Cassidy, chair of the Senate HELP Committee, released a report urging the FDA to reinstate in-person dispensing for mifepristone and accusing manufacturers of failing to meet legal responsibilities. The report targets abortion‑pill producers such as Danco Laboratories, GenBioPro and Evita Solutions, citing risks from online sales and potential coercion of women. Cassidy expressed concern over President Trump’s nomination of Dr. Heidi Overton to lead the FDA and highlighted the administration’s effort to block state lawsuits challenging mifepristone distribution policies. The report follows Cassidy’s recent confirmation vote for Todd Blanche as attorney general amid controversies over DOJ actions on abortion‑drug regulations. The Trump administration has paused multiple state lawsuits to roll back Biden‑era eased restrictions on mifepristone while awaiting a safety review.
about 1 month ago
Sen. Bill Cassidy, R-La., chair of the Senate Health, Education, Labor and Pensions Committee, released an Aug. 27 report criticizing the FDA’s oversight of mifepristone and questioning whether the drug’s manufacturers are complying with legal requirements. He called for reinstating in-person dispensing and stronger enforcement against prescribers and distributors, while abortion-rights advocates defended the drug’s safety and characterized the effort as part of a broader attempt to restrict abortion access.
The report followed a HELP Committee investigation into mifepristone manufacturers, including Danco Laboratories, GenBioPro and Evita Solutions. Cassidy said the companies may not be fulfilling their legal responsibilities to ensure compliance with remaining FDA requirements.
Cassidy specifically urged the FDA to restore the requirement that mifepristone be dispensed in person. He also called on the FDA and drug sponsors to take action against prescribers who violate prescribing rules, arguing that expanded online sales had increased the risk of coercion and abuse.
The report cited cases in which men allegedly ordered mifepristone online and coerced pregnant women into taking it. It also raised concerns about drugs being shipped nationwide, including for use later in pregnancy, citing reports involving third-trimester pregnancies.
Cassidy’s report came amid continuing disputes over regulatory changes made during the Biden administration, including allowing mifepristone to be shipped by mail. The Trump administration has sought to pause several state lawsuits challenging those changes while leaving the current rules in place pending a promised FDA safety review.
The issue is also connected to a lawsuit brought by Louisiana and other states. Arguments in State of Louisiana v. Food and Drug Administration were scheduled before the U.S. Fifth Circuit Court of Appeals for Sept. 9, and pro-life organizations have urged the Justice Department to settle the case.
Cassidy’s position has also intersected with the nomination of Dr. Heidi Overton to lead the FDA. Although Overton opposes abortion, Cassidy has expressed concerns about her role in the administration’s vaccine policies, leaving her confirmation prospects uncertain.
Mini Timmaraju, president and CEO of Reproductive Freedom for All, rejected the report’s conclusions. She said mifepristone is safe and accused Republicans of using their congressional majority to pursue a nationwide abortion ban.
Marjorie Dannenfelser, president of Susan B. Anthony Pro-Life America, said the report demonstrated that the harms associated with abortion drugs could not be addressed under current distribution practices. She urged Attorney General Todd Blanche to settle the Louisiana case and allow state abortion restrictions to take effect.
The FDA first approved mifepristone for early abortion in 2000. The medication is generally used with misoprostol in medication-abortion protocols and has also been used in some miscarriage-care protocols when a pregnancy has already ended.
The FDA approved a new generic version of mifepristone during the second Trump administration; the first Trump administration had approved the drug’s initial generic version. Supporters describe mifepristone as statistically safe and say restrictions would effectively eliminate medication abortion, while opponents cite safety concerns—particularly when the drug is obtained or used outside medical settings—and object to its use to end pregnancies.
Assess Catholic Church’s stance on mifepristone regulation
The Catholic Church opposes the use of mifepristone when it is intended to end a pregnancy, because it is part of a regimen that directly causes the death of an unborn human being. The Church therefore supports laws and regulations that protect unborn life, restrict or prohibit abortion, ensure truthful medical information, and protect healthcare workers’ conscientious refusal to participate.
The sources do not discuss mifepristone by name, but they establish principles that apply directly to abortion-inducing pharmaceuticals.
Catholic teaching holds that human life must be respected from conception. Direct abortion—whether chosen as an end or used as a means—is always gravely immoral because it deliberately kills an innocent human being. No circumstance, purpose, or civil law can make such an act morally licit.
The Church distinguishes ordinary contraception, which prevents conception, from an abortifacient drug, which acts after fertilization by preventing implantation or eliminating an implanted embryo. Such “interception” and “contragestation” are classified as abortion and are gravely immoral.
Accordingly, mifepristone used in a medication-abortion protocol falls under the Church’s opposition to direct abortion. The moral responsibility can extend beyond the person taking it to those who intentionally prescribe, dispense, fund, or otherwise directly cooperate in the abortion.
The Church’s position is not merely that Catholics should personally avoid mifepristone. It supports public policies that:
Thus, regulation should be protective rather than punitive alone. Pope Francis emphasized that women facing crisis pregnancies should feel “respected as a person, heard, accepted and supported,” while also insisting on opposition to direct attacks on unborn life.
Catholic moral analysis distinguishes direct abortion from legitimate treatment of a serious maternal illness. A procedure aimed at treating the mother’s pathology may be permissible if the child’s death is neither intended nor the means of achieving the treatment, even if it is foreseen as an unavoidable secondary consequence. A procedure that directly causes fetal death, however, is not permitted.
Therefore, the moral assessment depends on the treatment’s object and intention. Mifepristone used specifically to terminate an ongoing pregnancy is morally different from medical care that treats a separate pathology without intending the child’s death. The provided sources do not resolve every possible clinical use or protocol, so individual cases require competent medical and moral consultation.
The Catholic stance is clear: mifepristone used for direct abortion should not be morally supported, prescribed, dispensed, funded, or legally normalized. Regulation should protect unborn life, preserve informed consent and professional conscience, and provide substantial practical support for women and families. This position rests not on opposition to medicine or science, but on the principle that medical technology must serve the human person rather than treat one human life as disposable.